BioMed research international, 2016-01, Vol.2016, p.3242143-6
2016
Details
- Autor(en) / Beteiligte
- Titel
- No Significant Reduction of Circulating Endothelial-Derived and Platelet-Derived Microparticles in Patients with Psoriasis Successfully Treated with Anti-IL12/23
- Ist Teil von
- BioMed research international, 2016-01, Vol.2016, p.3242143-6
- Ort / Verlag
- United States: Hindawi Publishing Corporation
- Erscheinungsjahr
- 2016
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- Psoriasis is associated with atherosclerosis, in which circulating microparticles play an important role. In severe psoriasis, there was an increase of endothelial- and platelet- microparticles which could be decreased by anti-TNFα. However, whether anti-IL-12/23 treatment would decrease the level of microparticles remains unknown. Our study showed that, despite the clinical improvement of psoriasis after IL-12/13 blockage, the increased levels of circulating CD41a and CD31 microparticles were unchanged after anti-IL-12/23. This result suggested that anti-IL12/23 treatment may not alter the development of cardiovascular disease in patients with psoriasis.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2314-6133eISSN: 2314-6141DOI: 10.1155/2016/3242143Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4842038
- Format
- –
- Schlagworte
- Adult, Age, Aged, Arthritis, Atherosclerosis, Blood platelets, Blood Platelets - drug effects, Blood Platelets - immunology, Blood Platelets - pathology, Cardiac patients, Cardiovascular disease, Care and treatment, Cell-Derived Microparticles - drug effects, Cell-Derived Microparticles - immunology, Cell-Derived Microparticles - pathology, Clinical Study, Cloning, Dermatology, Development and progression, Diabetes, Endothelial Progenitor Cells - drug effects, Endothelial Progenitor Cells - immunology, Endothelial Progenitor Cells - pathology, Endothelium, Female, Hospitals, Humans, Hypertension, Inflammation, Inflammatory diseases, Interleukin-12 Subunit p40 - immunology, Male, Metabolism, Middle Aged, Pharmaceutical industry, Psoriasis, Psoriasis - blood, Psoriasis - immunology, Psoriasis - therapy, Rodents, Thrombosis, Treatment Outcome, Ustekinumab - administration & dosage, Ustekinumab - immunology